Selected article for: "acute lung injury and ARDS respiratory distress syndrome"
Author: Kost-Alimova, Maria; Sidhom, Eriene-Heidi; Satyam, Abhigyan; Chamberlain, Brian T.; Dvela-Levitt, Moran; Melanson, Michelle; Alper, Seth L.; Santos, Jean; Gutierrez, Juan; Subramanian, Ayshwarya; Byrne, Patrick J.; Grinkevich, Elizabeth; Reyes-Bricio, Estefanía; Kim, Choah; Clark, Abbe R.; Watts, Andrew J.B.; Thompson, Rebecca; Marshall, Jamie; Pablo, Juan Lorenzo; Coraor, Juliana; Roignot, Julie; Vernon, Katherine A.; Keller, Keith; Campbell, Alissa; Emani, Maheswarareddy; Racette, Matthew; Bazua-Valenti, Silvana; Padovano, Valeria; Weins, Astrid; McAdoo, Stephen P.; Tam, Frederick W.K.; Ronco, Luciene; Wagner, Florence; Tsokos, George C.; Shaw, Jillian L.; Greka, Anna
Title: A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury
  • Cord-id: 4qtquayo
  • Document date: 2020_10_29
    • ID: 4qtquayo
    Snippet: Drug repurposing has the advantage of identifying potential treatments on a shortened timescale. In response to the pandemic spread of SARS-CoV-2, we took advantage of a high-content screen of 3,713 compounds at different stages of clinical development to identify FDA-approved compounds that reduce mucin-1 (MUC1) protein abundance. Elevated MUC1 levels predict the development of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) and correlate with poor clinical outcomes. Our
    Document: Drug repurposing has the advantage of identifying potential treatments on a shortened timescale. In response to the pandemic spread of SARS-CoV-2, we took advantage of a high-content screen of 3,713 compounds at different stages of clinical development to identify FDA-approved compounds that reduce mucin-1 (MUC1) protein abundance. Elevated MUC1 levels predict the development of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) and correlate with poor clinical outcomes. Our screen identifies fostamatinib (R788), an inhibitor of spleen tyrosine kinase (SYK) approved for the treatment of chronic immune thrombocytopenia, as a repurposing candidate for the treatment of ALI. In vivo, fostamatinib reduces MUC1 abundance in lung epithelial cells in a mouse model of ALI. In vitro, SYK inhibition by the active metabolite R406 promotes MUC1 removal from the cell surface. Our work suggests fostamatinib as a repurposing drug candidate for ALI.

    Search related documents:
    Co phrase search for related documents
    • account variability and acute respiratory syndrome sars: 1, 2, 3
    • active concentration and acute respiratory syndrome sars: 1, 2, 3, 4
    • active form and acute ards respiratory distress syndrome: 1
    • active form and acute respiratory syndrome sars: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • active metabolite and acute ards respiratory distress syndrome: 1, 2
    • active metabolite and acute lung injury: 1
    • active metabolite and acute respiratory syndrome sars: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • activity range and acute phase: 1, 2, 3
    • activity range and acute respiratory syndrome sars: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • activity show and acute ards respiratory distress syndrome: 1, 2
    • activity show and acute lung injury: 1
    • activity show and acute respiratory syndrome sars: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25